REGULATORY
LDP Health Panel Holds Drug Pricing Hearing with Doctor, Pharmacist Groups
The ruling Liberal Democratic Party’s (LDP) committee on health, labor and welfare held a hearing with three major healthcare organizations including the Japan Medical Association (JMA) on the drug pricing overhaul sketched out by government ministers late last year. The…
To read the full story
Related Article
- LDP Health Panel to Compile Resolution on Drug Pricing
April 25, 2017
REGULATORY
- MHLW Taps Kawabata to Lead Drug Discovery Support Office
April 15, 2026
- MHLW Reviewing EMIS Data on Petro-Product Supply to Medical Institutions
April 15, 2026
- Japan Panel to Review Ferring Gene Therapy, Fujifilm Cell Product on April 20
April 14, 2026
- LDP, Ishin to Explore Role of Private Insurance in Reform Talks
April 14, 2026
- Middle East War Hitting API Air Freight, Trade Group Warns
April 13, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





